BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T020254
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220504
DTEND;VALUE=DATE:20220506
DTSTAMP:20260516T020254
CREATED:20220131T112354Z
LAST-MODIFIED:20220131T112354Z
UID:33057-1651622400-1651795199@www.pharmajournalist.com
SUMMARY:SMi’s 22nd Annual Pain Therapeutics Conference
DESCRIPTION:SMi’s 22nd Annual Pain Therapeutics Conference\nConference 4 – 5 May 2022\nWorkshop: 6 May 2022\nLondon\, UK\nhttp://www.pain-therapeutics.co.uk/PJwl\nSponsored by: CHDR \nConference Chairman: Richard Malamut\, Chief Medical Officer\, Collegium Pharmaceutical\, Inc \nNovel Compounds and Treatments for Pain: Opioids and the Alternatives  \nSMi’s 22nd Pain Therapeutics Conference will cover the leading advances in pain therapeutics\, exploring late development clinical trials\, novel treatments for chronic conditions\, technology collaboration treatments\, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field\, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore\, policy experts will provide an essential regulatory perspective for this year’s agenda\, providing an exciting and comprehensive insight into the pain therapeutics market. \nThe global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Million by 2026\, growing at a CAGR of 4.40 % from 2019 to 2026. \nThe pain industry was affected by Covid-19\, with many individuals suffering with pain conditions\, unable to get help or treatment. Therefore\, there has been a push to ensure that new and more effective treatments will be made available to patients. There is also still a need to move away from opioid based pain treatment. \nJoin Europe’s leading Pain Therapeutics Conference in May 2022 to explore new case studies and regulatory perspectives as well as uncover challenges and successes of both pre-clinical and clinical Pain R&D development to equip you with the necessary knowledge to advance R&D in the pain therapeutics industry. \nEvent hashtag: #SMiPain \nKey Reasons to Attend the Conference: \n\nDiscover the new treatments available for those with pain diseases\, such as migraine\, atopic dermatitis and muscle spasms\nDevelop your knowledge of analgesics for the treatment of pain\nDiscuss the new alternative treatments for pain and the use of opioids within the field\nNetwork with industry professionals and discuss recent advances in the industry\n\nView the full agenda: http://www.pain-therapeutics.co.uk/PJwl \nWho Should Attend? \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nWorkshop: Friday 6 May 2022\nMolecular and Cellular Pathophysiology of Pain Resolution \nWorkshop Leaders: \nLuda Diatchenko\, Canada Research Chair in Human Pain Genetics\, Department of Anesthesia\, Faculty of Medicine\, McGill University \nJulio Reinecke\, Chief Scientific Officer and Co-Founder\, Orthogen \nPeter Wehling\, CEO and Founder\, Orthogen \nRu-Rong Ji\, Professor in Anesthesiology\, Distinguished Professor of Anesthesiology\, Professor in Neurobiology\, Professor in Cell Biology\, School of Medicine\, Duke Neurobiology
URL:https://www.pharmajournalist.com/event/smis-22nd-annual-pain-therapeutics-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR